Ian McCaffery
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Adenosine and Purinergic Signaling, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project(2016)1,237 cited
- → Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer(2019)326 cited
- → Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1(2009)307 cited
- → Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma(2016)296 cited
- → Phase II Study of Ganitumab, a Fully Human Anti–Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors(2012)218 cited
- → A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models(2018)210 cited
- → Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab(2018)186 cited
- → Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial(2013)164 cited
- → Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells(2010)137 cited
- → Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer(2014)107 cited